What prices were involved in the Spyre Therapeutics (SYRE) CFO’s option exercise and share sales?

The CFO exercised options at an exercise price of $14.50 per share to obtain 7,500 shares. He then sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98, all in open-market transactions.

Spyre Therapeutics (SYRE) CFO exercises options and sells 7,500 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Spyre Therapeutics Chief Financial Officer Scott L. Burrows reported an option exercise and related stock sales. On April 1, 2026, he exercised stock options to acquire 7,500 shares of common stock at an exercise price of $14.50 per share, fully using the remaining options covered in this filing.

On the same date, he sold 6,200 shares at a weighted average price of $49.21 and 1,300 shares at a weighted average price of $49.98 in open-market transactions, executed under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he directly held 97,994 shares of common stock, including 67,476 restricted stock units scheduled to vest in equal installments on September 1, 2026 and September 1, 2027, subject to continued employment.

Insider Trade Summary 10b5-1

Net Seller: 7,500 shares ($370,076)

Net Sell 4 txns

Insider Burrows Scott L

Role Chief Financial Officer

Sold 7,500 shs ($370K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	7,500	$0.00	--
Exercise	Common Stock	7,500	$14.50	$109K
Sale	Common Stock	6,200	$49.21	$305K
Sale	Common Stock	1,300	$49.98	$65K

Holdings After Transaction: Stock Option (Right to Buy) — 394,857 shares (Direct); Common Stock — 105,494 shares (Direct)

Footnotes (1)

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Key Figures

Options exercised: 7,500 shares at $14.50 Shares sold (block 1): 6,200 shares at $49.21 Shares sold (block 2): 1,300 shares at $49.98 +2 more

5 metrics

Options exercised 7,500 shares at $14.50 Stock option exercise on April 1, 2026

Shares sold (block 1) 6,200 shares at $49.21 Weighted average sale price on April 1, 2026

Shares sold (block 2) 1,300 shares at $49.98 Weighted average sale price on April 1, 2026

Shares held after transaction 97,994 shares Direct common stock holdings after April 1, 2026 trades

Restricted stock units 67,476 RSUs RSUs vesting in equal installments on Sept 1, 2026 and 2027

Key Terms

Rule 10b5-1 trading plan, restricted stock units ("RSUs"), weighted average price, reverse stock split, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units ("RSUs") financial

"Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

weighted average price financial

"The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

reverse stock split financial

"shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023)"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

stock option (Right to Buy) financial

"This option represents a right to purchase 404,857 shares of the Issuer's common stock"

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 09:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burrows Scott L

(Last)

(First)

(Middle)

221 CRESCENT STREET, BUILDING 23,

SUITE 105

(Street)

WALTHAM

MASSACHUSETTS

02453

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Spyre Therapeutics, Inc. [ SYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		M⁽¹⁾		7,500	A	$14.5	105,494	D
Common Stock	04/01/2026		S⁽¹⁾		6,200	D	$49.21⁽²⁾	99,294	D
Common Stock	04/01/2026		S⁽¹⁾		1,300	D	$49.98⁽³⁾	97,994⁽⁴⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.5	04/01/2026		M⁽¹⁾			7,500	⁽⁵⁾	09/01/2033	Common Stock	7,500	$0	394,857	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.

2. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

3. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

5. This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

	/s/ Heidy King-Jones, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Spyre Therapeutics (SYRE) report for its CFO?

Spyre Therapeutics reported that CFO Scott L. Burrows exercised stock options for 7,500 shares at $14.50 per share, then sold 6,200 shares at a weighted average of $49.21 and 1,300 shares at $49.98 in open-market trades on April 1, 2026.

Was the Spyre Therapeutics (SYRE) CFO’s stock sale part of a Rule 10b5-1 plan?

Yes. The filing states the transactions were executed under a Rule 10b5-1 trading plan adopted on November 10, 2025. Such plans pre-schedule trades, making the timing more routine and less tied to short-term information about Spyre Therapeutics’ business.

How many Spyre Therapeutics (SYRE) shares does the CFO hold after these transactions?

After the reported transactions, CFO Scott L. Burrows directly holds 97,994 shares of Spyre Therapeutics common stock. This total includes 67,476 restricted stock units that may convert into shares over time if vesting conditions and continued employment requirements are satisfied.

What are the terms of the Spyre Therapeutics (SYRE) CFO’s restricted stock units?

The CFO holds 67,476 restricted stock units, each representing a contingent right to receive one share of common stock. These RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to his continued employment with Spyre Therapeutics.

How were the Spyre Therapeutics (SYRE) CFO’s sale prices calculated in the Form 4?

The reported sale prices are weighted averages. The 6,200 shares were sold in multiple trades between $48.69 and $49.63, and the 1,300 shares between $49.76 and $50.15. Detailed per-trade pricing is available on request from the company or the SEC.